| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer
1 Department of Medicine (Heme/Onc),
2 Abramson Cancer Center,
3 Abramson Family Cancer Research Institute,
4 Department of Biostatistics and Epidemiology, University of Pennsylvania,
5 Department of Pathology, Pennsylvania Hospital, Philadelphia, Pennsylvania
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
is a proinflammatory cytokine that also plays a role in regulating IL-6 transcription. We hypothesized that polymorphisms in IL-6 (-174 G>C) or TNF- (G-238 or G-308) might be associated with prognosis in a subset of patients with high-risk breast cancer. Genotyping was performed on DNA from stored stem cells in 80 breast cancer patients diagnosed with at least four positive axillary lymph nodes at diagnosis who underwent anthracycline-based adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem cell rescue. Cox proportional hazards models were used to estimate the effect of genotype and other known prognostic factors on disease-free and overall survival (DFS and OS, respectively).
The presence of at least one C allele in the IL-6 promoter at position -174 was significantly associated with both DFS and OS compared with G/G homozygotes. After adjustment for estrogen receptor (ER) status, number of involved lymph nodes, and tumor size, those patients carrying the G/G genotype had a 2.1-fold increase in the rate of failure and a 2.6-fold increase in the rate of death compared with carriers of any C allele at a mean follow-up of 55 months. ER status modulated the effect of IL-6 polymorphism: both DFS and OS were most favorable in patients who were carriers of any C-allele (G/C or C/C) and had ER-positive tumors. The presence of either G/G genotype or an ER-negative tumor increased the hazard of failure [hazard ratio (HR), 2.6 and 3.2, respectively] and death (HR, 2.0 and 2.2, respectively). The combination of both G/G genotype and ER-negative tumor resulted in an additional increase in the hazard of failure (HR, 5.4; four-group comparison, P = 0.003) and death (HR, 6.2; four-group comparison, P = 0.001). TNF- -308 and -238 polymorphisms were not associated with variation in DFS or OS in this cohort.
The IL-6–174 promoter polymorphism is associated with clinical outcome in this cohort of node-positive breast cancer patients who received high-dose adjuvant therapy. IL-6 genotype modulated the effect of ER status on outcome. These results support the hypothesis that IL-6 may play an important role in the control of micrometastatic disease in breast cancer. Additional studies are needed to confirm these results and elucidate the mechanisms responsible for these differences.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
33% overall. These approaches typically involve the use of chemotherapeutic and/or hormonal agents. More recently, high-dose chemotherapy with peripheral stem cell rescue has been used in high-risk patients, but current data suggest that this approach, whereas feasible, does not confer significant advantages in DFS6
or OS in breast cancer patients. Moreover, systemic adjuvant chemotherapy can result in substantial short- and long-term toxicities that may adversely affect quality of life for breast cancer survivors. There is a need for biomarkers that can reliably identify patients who: (a) will clearly benefit from current adjuvant systemic therapy such that the benefits outweigh potential risks; (b) have been cured with surgical resection and therefore do not need adjuvant therapy; or (c) will recur despite standard therapies and are, thus, candidates for investigational approaches. Currently available clinical and molecular prognostic tools provide some information on the risk of recurrence among poor-prognosis breast cancer patients. Work in this area has primarily focused on molecular and genetic tumor alterations that influence response to treatment and ultimate clinical outcome. Hormone receptors (estrogen and progesterone receptors) as well as HER-2/neu overexpression are well-validated tumor markers that can provide important prognostic information as well as predict response to therapies such as tamoxifen or Herceptin. Many other tumor markers, including proteins involved in cell cycling and angiogenesis, are being validated currently in this setting.
We hypothesized that host (patient) factors may also play an important role in determining risk of recurrence by influencing the milieu in which microscopic residual tumor cells are able to proliferate. We have approached the search for new prognostic markers by examining associations between clinical outcome and host genetic variants that might subsequently affect the response of the body to microscopic residual cancer.
Immune surveillance is one such host process that may influence recurrence, because several cytokines have been implicated in mediating this process. IL-6 is a pleiotropic, proinflammatory cytokine that may be involved in the host response to cancer. In vitro data suggest that cytokines such as IL-6 may provide a growth stimulus for breast cancer cells through as-yet unidentified mechanisms. In metastatic breast cancer, high serum IL-6 levels have been associated with a greater number of metastatic sites (1) , poorer clinical outcome (1) , lack of response to therapy (2) , resistance to chemotherapy (3) , and resistance to hormonal therapy (4) .
Polymorphic variants in the promoter region of the IL-6 gene may be responsible for variations in transcription that subsequently affect serum levels of the cytokine. The best characterized of these polymorphisms is a SNP at position -174, upstream of the transcription start site, involving substitution of cytosine for guanine (henceforth referred to as IL-6–174 G/C). Presence of the "G" allele has been associated with poor outcome in a variety of diseases, including coronary artery disease (5) , graft versus host disease after allogeneic bone marrow transplant (6) , more severe manifestations of Sjogren syndrome and systemic lupus erythromatosis (7) , and increased risk of juvenile rheumatoid arthritis (8) .
We hypothesized that IL-6 might play a role in the control of residual microscopic disease among women with high-risk breast cancer and, thus, impact natural history of the disease among aggressively treated patients. We investigated associations between clinical outcome and the IL-6–174 G/C polymorphism in patients who had been diagnosed with node-positive, poor-prognosis breast carcinoma. Because IL-6 production is in part controlled by TNF-, we also examined two functional polymorphisms in the TNF- promoter, -238G>A and -308G>A. The primary aim of the current study was to determine whether there were associations between these polymorphisms and either DFS or OS in a population of women with high-risk breast cancer who received a uniform treatment regimen consisting of standard anthracycline-containing chemotherapy followed by high dose chemotherapy. A secondary aim of the study was to evaluate whether the impact of genotype on outcome differed by ER expression in the tumor.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
4 positive nodes) enrolled previously on one of two clinical trials at the University of Pennsylvania Cancer Center from June 1992 through December 1997. Subjects consenting for these protocols had concurrently consented to the use of their stem cell materials for clinical research. All of the patients in the current study received conventional adjuvant chemotherapy with an anthracycline-containing regimen followed by bone marrow and/or peripheral blood stem cell harvest. After harvest, bone marrow or stem cells were resuspended in a combination of 10% DMSO and autologous plasma before storage at -140°C. The high-dose chemotherapy regimen consisted of concurrent cyclophosphamide 1500 mg/m2 as a continuous infusion daily for 4 days and thiotepa 200 mg/m2 as a continuous infusion daily for 4 days. Thawed bone marrow or stem cells were reinfused through a central venous catheter at least 48 h after completion of chemotherapy. Patients with positive estrogen and/or progesterone receptors were treated with tamoxifen, 20 mg/day, after hematopoietic recovery. Patients received radiation treatment to the breast or chest wall, and to ipsilateral axillary and supraclavicular lymphatics either before high-dose therapy or after hematopoietic recovery. Patients were followed for recurrence and death.
Genomic DNA was extracted from residual stem cell or bone marrow samples available from the University of Pennsylvania Department of Pathology. Subject samples were identified by sample identification number only, and clinical information was assigned a study identification number. Thus, clinical outcome data were not available to laboratory personnel, and no patient identifiers were linked to clinical data. DNA isolation was performed using the Purgene DNA Isolation kit (Genta, Inc.) according to the manufacturer’s guidelines with minor modifications. The DNA was then stored at 4°C for short-term storage, or between -20°C and -80°C for long-term storage. PCR reactions were used to amplify the regions containing the polymorphisms of interest. The primers 5'-ATGCCAAGTGCTGAGTCACTA-3' (in the forward direction) and 5'-TCGAGGGCAGAATGAGCCTC-3' (in the reverse direction) were used to amplify the region containing the IL-6 -174G>C variant. The primers 5'-CAAACACAGGCCTCAGGACTCAACA-3' (forward direction) and 5'-CTGCACCTTCTGTCTCGGTTTCTTC-3' (reverse direction) were used to amplify the region containing the TNF- variant. PCR amplification was performed in a final volume of 20 µl containing 80 ng of DNA, 1.5 mM of MgCl2, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.2 mM each of dCTP, dATP, dTTP, dGTP (Amersham Pharmacia Biotech), each primer at 1.0 µM, and 1.0 unit of Taq polymerase (Boehringer Mannheim) in a 9700 Perkin-Elmer/Cetus Thermocycler.
For the IL-6 G-174C polymorphism, 10 µl of the PCR product was digested with 2 units of NlaIII using the manufacturer’s recommended protocol. PCR products were visualized on 3% agarose gels with 10% ethidium bromide. PCR products for the IL-6 polymorphism were analyzed by RFLP analysis (Fig. 1)
and subsequent confirmation of variants by direct sequencing. PCR products for the TNF- polymorphism were analyzed by direct sequencing.
|
Associations between a polymorphism and DFS or OS were assessed by the log rank test. Cox regression analysis (9) was used to estimate the HR for the IL-6 polymorphism, adjusting for other prognostic variables, as well as to test for interaction between IL-6 polymorphism and ER status. All tests of significance are two-sided. Analyses were performed in SPSS (SPSS Inc., Chicago, IL).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Clinical characteristics of the 80 patients with analyzable DNA samples are summarized in Table 1
. The median age was 43 (range, 24–60). Median tumor size was 3 cm (range, 0.8–9.4 cm). Eighty-one percent of the cohort had at least 10 positive lymph nodes (n = 65), with the remainder (n = 15) having between 4 and 9 positive lymph nodes. The median number of positive lymph nodes was 16 (range, 4–42). More than half were ER positive (59%) and/or progesterone receptor positive (48%). DFS and OS curves for the entire study cohort (n = 80) are shown in Fig. 2
. Median follow-up time for all 80 of the patients was 55 months; median follow-up time for those 53 patients alive at last follow-up is 50 months. As of May 2002, 32 patients (40%) had a recurrence of breast cancer; 44 patients (55%) remained disease-free. Disease status before death was unknown on 4 patients (5%). Fifty-three patients (66%) remain alive, and 27 patients were confirmed as deceased. Median DFS for the cohort studied was 68 months. Median OS time has not yet been reached.
|
|
polymorphisms, -238G>A and -308G>A (Table 2)
. Variants in the IL-6 gene were most common (64% total; 49% heterozygous G/C and 15% homozygous C/C) with proportions similar to published distributions in the general population (8)
. TNF- polymorphisms were less frequent, with 9% having a -238 A variant and 35% having a -308 A variant. For most analyses of the IL-6 polymorphism, carriers of homozygous and heterozygous variants were pooled (due to small numbers of patients with the C/C genotype) and compared with WT G/G homozygotes.
|
, patients without at least one C allele in the IL-6–174 promoter region had a 4-year DFS of 45% (±10%) compared with 65% (±7%) among patients with at least one C allele (P = 0.02). Among the 29 patients homozygous for the G allele at the IL-6 promoter locus, median DFS was 39 months. Median DFS for G/C plus C/C carriers has not yet been reached. Patients homozygous for the G allele (G/G) had a significantly increased risk of recurrence compared with those with the IL-6 polymorphism (G/C or C/C; HR, 2.2; 95% CI, 1.1–4.1; P = 0.02; Fig. 3
). DFS was not significantly different between carriers of either TNF- variant compared with those with the WT genotype (Table 3)
.
|
|
, patients homozygous for the G allele (G/G) in the IL-6–174 promoter region had a 4-year OS of 51% (±10%) compared with 77% (±6%) among patients with at least one C allele. Patients who were homozygous for the G allele (G/G) had a significantly increased risk of death compared with those with at least one C allele (G/C or C/C; HR, 2.6; 95% CI, 1.2–5.6; P = 0.01; Fig. 4
). OS was not significantly different among carriers of either TNF- variant compared with those with the WT genotype (Table 3)
. Univariate associations between other prognostic factors and DFS, OS, and the IL-6 polymorphism were tested (Table 4)
. As expected, ER status (negative versus positive) was found to be significantly associated with both DFS (P = 0.004) and OS (P = 0.009). There were no significant associations between either lymph node number (4–9 versus >10 positive nodes) or tumor size (<2 cm versus 2–5 cm versus >5 cm) and DFS or OS in this cohort. Whereas patients with more nodes (10) or larger tumors had HRs slightly below 1.0, these findings were not significant as indicated by the CIs spanning 1.0. IL-6 genotype was not significantly associated with any of the other tumor factors studied (data not shown.).
|
|
. The multivariate model consisted of the IL-6 polymorphism in addition to known prognostic factors: ER status, lymph node group, and tumor size. The inclusion of other prognostic factors in the model did not impact on the relationship between IL-6 polymorphism and outcome (as demonstrated by similar unadjusted and adjusted HRs for IL-6 polymorphism); patients with the G/G genotype had a 2.1-fold increase in the hazard of developing a recurrence over the study period (95% CI, 1.05–4.1; P = 0.035) and a 2.6-fold increase in the hazard of death (95% CI, 1.2–5.8; P = 0.02) after adjusting for other factors. Of the additional variables considered, only ER status was significantly associated with DFS and/or OS; those with ER-negative tumors had a 3.2-fold increase in hazard of developing a recurrence (95% CI, 1.5–6.8; P = 0.002) and a 3.4-fold increase in the hazard of death (95% CI, 1.4–8.1; P = 0.005) after adjustment for other factors, including IL-6 genotype.
Because of the observed significant association between ER and outcome, as well as our a priori hypothesis that IL-6 may be exerting its effect through hormonally mediated pathways, we examined more closely the interaction between ER status and IL-6 polymorphism on both DFS and OS (Table 5)
. For DFS (Fig. 5)
, the most favorable outcome was seen in patients whose tumors were ER positive and who were carriers of at least one C-allele (G/C or C/C). Having either G/G genotype or absence of tumor ER increased the hazard for failure (HR, 2.6 and HR, 3.2, respectively), and the combination of both these factors resulted in an additional increase in the HR (HR = 5.4; four-group comparison, P = 0.003). Similarly, for OS (Fig. 6)
, having either G/G genotype or absence tumor ER increased the hazard for death (HR, 2.0 and HR, 2.2, respectively), and the combination of both these factors resulted in an additional increase in the HR (HR, 6.2; four-group comparison P = 0.001). Thus, the ER status and IL-6 promoter polymorphism clearly had a significant combined effect on both DFS and OS, although tests of interaction were not significant (P = 0.5 and P = 0.65, respectively), possibly due to the small sample size.
|
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Several studies have found a link between IL-6 levels and breast cancer outcome, although none to date have demonstrated that genetic polymorphisms in the IL-6 promoter region correlate with prognosis. Zhang and Adachi (1) demonstrated that serum IL-6 levels are higher in patients with more numerous metastatic sites and poorer clinical outcome. Several other studies have found associations between higher serum IL-6 levels and poor response to breast cancer therapy (2) , including resistance to both chemotherapy (3) and hormonal therapies (4) . However, many factors influence production of cytokines and subsequent serum levels, which can confound the relationship between these substances and outcomes. Our study, significantly linking a polymorphism in the gene encoding IL-6 provides additional important information linking IL-6 to breast cancer growth and progression.
The presence of a SNP in the promoter of IL-6 is only likely to influence clinical outcome if the presence or absence of the SNP alters gene expression and subsequent activity or quantity of the gene product in the serum. Several studies have attempted to link IL-6–174G/C genotype to serum levels, both in normal subjects, and in those suffering either chronic disease or acute illness. Fishman et al. (8) studied plasma levels of IL-6 in 102 healthy subjects, and the C allele was found to be associated with significantly lower levels of plasma IL-6. Hulkkonen et al. (7) , studying 111 patients with Sjogrens Syndrome, found that IL-6 plasma levels were higher in the patients with the G/G genotype (5.35 + 3.01 pg/ml) compared with those carrying G/C (3.96 ± 2.71 pg/ml) or C/C (3.52 ± 2.40 pg/ml; G/G versus C/C, P < 0.05). Bonafe et al. (11) found a similar association in 269 subjects age 70 or over in Italy. Differences in serum levels were analyzed by age group and gender. In all three of the age groups (60–80, 81–99, and >99), men without at least one C allele had higher IL-6 serum levels than male C allele carriers. Whereas these studies support the hypothesis that IL-6 serum exposure may vary by genotype, two additional studies have failed to find this association (12 , 13) . It is possible that these studies failed to find the association between genotype and spot serum IL-6 for several reasons. First, there is tremendous intraindividual variation in IL-6 level, even in nonpathological circumstances. Second, IL-6 levels may be influenced by medications (8) . Third, other factors, such as age and nutritional status, may impact IL-6 levels. These issues beg the question, can differences in cumulative IL-6 exposure be reliably detected by measurement of serum level in isolated points in time? We conclude that the available in vivo data demonstrating lower IL-6 levels in carriers of the IL-6–174 G/C SNP are strongly suggestive, and that more robust data may only come from additional in vitro study of the impact of the SNP on transcriptional activity. Unfortunately, serum was not available in our study cohort, and, thus, IL-6 measurements could not be performed in the current study.
It is thought that circulating levels of IL-6 are largely regulated at the level of expression due to the rapid plasma clearance of this cytokine (14) . Results of several studies support the notion that the IL-6–174G/C SNP is a functional alteration that affects gene transcription and subsequent serum levels of IL-6 cytokine. Recent data from Belluco et al. (15) demonstrates that circulating IL-6 levels are significantly higher in IL-6–174 G/G homozygotes with colon cancer compared with carriers of a C allele, and correlated significantly with the presence of hepatic metastases. Fishman et al. (8) reported the first population-based study examining IL-6–174G/C genotype, plasma IL-6 level, and clinical outcome in juvenile chronic arthritis in the United Kingdom. They found that when comparing constructs of the 5' flanking region in a luciferase reporter vector transiently transfected in HeLA cells, the -174C construct showed 0.15-fold lower expression than the t174G construct. After stimulation with lipopolysaccharide or IL-1, expression from the -174C construct did not significantly change after 24 h (increase of 0.10-fold), whereas expression from the 174G construct increased significantly by 0.26-fold (P = 0.0001). Terry et al. (16) confirmed these findings in an elegant study examining the functional effects of four separate SNPs in the IL-6 promoter (including -174G/C) transfected into both HeLa cells and the ECV304 cell line. This study showed that more than one of the polymorphic sites was functional, but when the -174G/C polymorphism was considered alone, variants containing a C allele showed lower expression than the G/G genotype. Taken together, these studies provide evidence of an enhancement in transcription of IL-6 associated with the G-allele, additionally supporting the serum findings described above, and providing a basis for the use of genotype as a surrogate marker of cumulative IL-6 exposure in the current study.
Our finding of an additive effect of ER status in the tumor and IL-6 polymorphism in the host provides additional support for the hypothesis that IL-6 exerts its effect on breast cancer cells at least in part through hormonal pathways. Cytokines, such as IL-6 and TNF-, have an important role in regulating estrogen synthesis in peripheral tissues, including normal and malignant breast tissues (17)
. In vitro, the activities of aromatase, estradiol, 17-ß-hydroxysteroid dehydrogenase, and estrone sulfatase are all increased by IL-6 and TNF-. This mechanism could in part explain the worse prognosis among ER-positive patients with the G/G genotype in our study, and warrants additional research.
These findings, whereas important, are preliminary. The small sample size requires that these findings be viewed as exploratory and interpreted in context. We did not have prospectively documented information on race in the study database, and, thus, could not assess whether the associations between IL-6 genotype and clinical outcome remain after adjustment for race. Moreover, the distribution of race/ethnicity in the breast cancer population of the study site consists of 86% Caucasian, 9% African American, and 5% other. Thus, if the study population reflected this overall patient population, our small sample size would likely have precluded any formal analyses by race or ethnicity.
Three patients in our study died during the immediate post-transplant period due to complications of treatment and were, thus, excluded from the disease-related outcomes of interest. All 3 of the patients were homozygous for the "poor prognosis" (G/G) IL-6–174 polymorphism, thus inclusion of these patients would likely have strengthened the association between genotype and outcome. Future studies should consider including toxicity as a disease outcome that might be associated with genotype, as IL-6-mediated inflammation may play a role in the development of treatment-related morbidity.
Characteristics of the breast tumors of our study patients might have shed additional light on the mechanisms by which an association between IL-6 production and microscopic tumor growth might operate. In vitro data suggest that inflammatory cytokines provide signals for tumor cells, operating through specific cell membrane receptors to trigger intracellular signaling pathways rather than simply as regulators of the inflammatory response (18 , 19) . IL-6 signaling occurs through both IL-6 receptors (20) and via crosstalk between the IL-6 gp130 signal transducing subunit and other membrane receptors, including the HER family of receptor tyrosine kinases (18 , 20) . A soluble IL-6R has been identified that has paracrine activity (21) , also signaling through gp130. These interactions are thought to be important for modulation and amplification of cytokine signaling in tumor-specific settings. Unfortunately, tumor samples were not available on this retrospective cohort. Future prospective studies are needed to evaluate whether tumor cells themselves contain increased IL-6 receptor or cytokine, whether tumor-infiltrating lymphocytes express IL-6 mRNA, or whether IL-6 genotype is associated with alterations in cell signaling pathways in breast tumors, resulting in detrimental physiological effects on residual microscopic breast cancer cells in node-positive patients.
Finally, as with any observational study of this type, our findings of an association between IL-6 genotype and breast cancer outcomes may have resulted from the linkage of this polymorphism with another susceptibility locus rather than from a direct causal effect. A single observational study is not sufficient to determine a causal link, despite a biologically plausible hypothesis and strong, independent association. Findings of an association between the IL-6 -174 promoter polymorphism and outcome in a variety of other diseases, including coronary artery disease (22) and autoimmune diseases (7) , suggest that this SNP may have functional consequences, but additional work is clearly necessary to both confirm our findings in breast cancer and to elucidate the functional consequences of IL-6–174 promoter polymorphisms in this patient population.
|
FOOTNOTES |
|---|
Requests for reprints:Angela DeMichele, Department of Medicine, Rowan Breast Center of the Abramson Center, 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104. Phone: (215) 349-5730; Fax: (215) 615-3349; E-mail: dma{at}mail.med.upenn.edu.
6 The abbreviations used are: DFS, disease-free survival; OS, overall survival; IL, interleukin; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor; RFLP, restriction fragment length polymorphism; ER, estrogen receptor; WT, wild-type; HR, hazard ratio; CI, confidence interval. 
Received 2/10/03. Revised 8/ 1/03. Accepted 8/19/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood, 98: 1594-1600, 2001.This article has been cited by other articles:
|
|
 |
|
  J. P. Lagmay, W. B. London, T. G. Gross, A. Termuhlen, N. Sullivan, A. Axel, B. Mundy, M. Ranalli, J. Canner, P. McGrady, et al. Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma: rs1800795 (Promoter) and rs8192284 (Receptor) Clin. Cancer Res., August 15, 2009; 15(16): 5234 - 5239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Cole Chronic Inflammation and Breast Cancer Recurrence J. Clin. Oncol., July 20, 2009; 27(21): 3418 - 3419. [Full Text] [PDF]
|
|
|
|
 |
|
 A. DeMichele, R. Gray, M. Horn, J. Chen, R. Aplenc, W. P. Vaughan, and M. S. Tallman Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer Cancer Res., May 15, 2009; 69(10): 4184 - 4191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Studebaker, G. Storci, J. L. Werbeck, P. Sansone, A. K. Sasser, S. Tavolari, T. Huang, M. W.Y. Chan, F. C. Marini, T. J. Rosol, et al. Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner Cancer Res., November 1, 2008; 68(21): 9087 - 9095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Poulain, I. Dervite, X. Leleu, V. Coiteux, P. Duthilleul, and P. Morel The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less Haematologica, July 1, 2008; 93(7): 1109 - 1111. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wilkening, B. Tavelin, F. Canzian, K. Enquist, R. Palmqvist, A. Altieri, G. Hallmans, K. Hemminki, P. Lenner, and A. Forsti Interleukin promoter polymorphisms and prognosis in colorectal cancer Carcinogenesis, June 1, 2008; 29(6): 1202 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Liao, J.-T. Lin, C.-Y. Wu, S.-P. Huang, M.-T. Lin, A. S.-H. Wu, Y.-J. Huang, and M.-S. Wu Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma Clin. Cancer Res., January 15, 2008; 14(2): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer FASEB J, November 1, 2007; 21(13): 3763 - 3770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Udler, A.-T. Maia, A. Cebrian, C. Brown, D. Greenberg, M. Shah, C. Caldas, A. Dunning, D. Easton, B. Ponder, et al. Common Germline Genetic Variation in Antioxidant Defense Genes and Survival After Diagnosis of Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Slattery, K. Curtin, R. Baumgartner, C. Sweeney, T. Byers, A. R. Giuliano, K. B. Baumgartner, and R. R. Wolff IL6, Aspirin, Nonsteroidal Anti-inflammatory Drugs, and Breast Cancer Risk in Women Living in the Southwestern United States Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, A. McMillan, J. Wiencke, J. Wiemels, K. Kelsey, J. Patoka, H. Jones, V. Carlton, R. Miike, J. Sison, et al. Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis Clin. Cancer Res., January 1, 2007; 13(1): 197 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Howell and M. J. Rose-Zerilli Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis J. Nutr., January 1, 2007; 137(1): 194S - 199S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grimm, L. Six, C. Tomovski, P. Speiser, E. Joura, R. Zeillinger, G. Sliutz, A. Reinthaller, and L. A. Hefler A Common Interleukin-6 Promoter Polymorphism in Patients With Vulvar Cancer Reproductive Sciences, December 1, 2005; 12(8): 617 - 620. [Abstract] [PDF]
|
|
|
|
|
|
A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Leibovici, H. B. Grossman, C. P. Dinney, R. E. Millikan, S. Lerner, Y. Wang, J. Gu, Q. Dong, and X. Wu Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival J. Clin. Oncol., August 20, 2005; 23(24): 5746 - 5756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hefler, C. Grimm, T. Lantzsch, D. Lampe, S. Leodolter, H. Koelbl, G. Heinze, A. Reinthaller, D. Tong-Cacsire, C. Tempfer, et al. Interleukin-1 and Interleukin-6 Gene Polymorphisms and the Risk of Breast Cancer in Caucasian Women Clin. Cancer Res., August 15, 2005; 11(16): 5718 - 5721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bhanoori, K. A. Babu, M. Deenadayal, S. Kennedy, and S. Shivaji The Interleukin-6 -174G/C Promoter Polymorphism Is Not Associated With Endometriosis in South Indian Women Reproductive Sciences, July 1, 2005; 12(5): 365 - 369. [Abstract] [PDF]
|
|
|
|
 |
|
 M.J. BISSELL, P.A. KENNY, and D.C. RADISKY Microenvironmental Regulators of Tissue Structure and Function Also Regulate Tumor Induction and Progression: The Role of Extracellular Matrix and Its Degrading Enzymes Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 343 - 356. [Abstract] [PDF]
|
|
|
|
|
|
A. Huber, C. Grimm, S. Jirecek, R. Zeillinger, K. Heim, P. Husslein, and L. Hefler An lnterleukin-6 Gene Promoter Polymorphism and Unexplained Late Intrauterine Fetal Death: A Multicenter Study Reproductive Sciences, January 1, 2005; 12(1): 33 - 36. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bennermo, C. Held, S. Stemme, C.-G. Ericsson, A. Silveira, F. Green, and P. Tornvall Genetic Predisposition of the Interleukin-6 Response to Inflammation: Implications for a Variety of Major Diseases? Clin. Chem., November 1, 2004; 50(11): 2136 - 2140. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
